Use access key #2 to skip to page content.
$6.33 0.04 (0.64%)
7/3/2008 1:00 PM

Halozyme Therapeutics, Inc. (HALO)

CAPS Rating:
**

A biopharmaceutical company dedicated to the development and commercialization of recombinant human enzymes for the drug delivery, palliative care, oncology and infertility markets.

View All Commentary (HALO)

Recs

0

Avatar zzlangerhans (70.51) Submitted: 10/22/07 6:14 AM : Outperform Start Price: $8.80 HALO Score: -12.92

Price has not increased much since announcement of Roche deal in 12/06, despite several positive developments. Given the strong partnerships and solid technology, stock will likely gap up again with good data from Baxter or Roche. Company is also an acquisition candidate for Baxter which is currently cash-heavy.

Report this Post Replies: 0 | Reply

Featured Broker Partners